N/A
Completed N=26
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)
Source: ClinicalTrials.gov NCT00725452 ↗Enrolled (actual)
26
Serious AEs
7.7%
Results posted
Sep 2011
Primary outcomePrimary: Number of Therapies That Were Applied as Induction, Maintenance, or Episodic Therapies After One Infusion of Infliximab — 7; 2; 1; 2 Therapies
Summary
Prospective, open-label-, 1-arm, multicenter observational study to determine the dose and interval of Infliximab infusions for subjects with plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Therapies That Were Applied as Induction, Maintenance, or Episodic Therapies After One Infusion of Infliximab |
7; 2; 1; 2 | — |
| SECONDARY Mean Time Interval Between Infliximab Infusions During Maintenance Treatment Following Induction Therapy |
49.25; 57.25; 59.67; 55.00; 56.00; 55.50 | — |
| SECONDARY Median Time Interval Between Infliximab Infusions During Maintenance Treatment Following Induction Therapy |
56.00; 56.00; 56.00; 56.00; 56.00; 55.50 | — |
| SECONDARY Mean Dose of Infliximab |
4.55; 4.66; 4.67; 4.58; 4.51; 4.41 | — |
| SECONDARY Median Dose of Infliximab |
4.88; 5.00; 5.00; 5.00; 4.91; 4.71 | — |
| SECONDARY Mean Percent Change From Baseline in Body Surface Area (BSA) Involved With Psoriasis After Treatment With Infliximab |
38.63; -11.17 | — |
Eligibility Criteria
Inclusion Criteria
- According to the European Summary of Product Characteristics (SPC): Adult subjects with moderate-to-severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapy including cyclosporine, methotrexate, or Psoralen-ultraviolet-A light (PUVA).
Exclusion Criteria
- According to the European SPC:
- Subjects with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections.
- Subjects with moderate-to-severe heart failure (New York Heart Association (NYHA) class III/IV).
- Subjects with a history of hypersensitivity to Infliximab or to other murine proteins or to any of the excipients.
- Subjects with elevated liver enzymes (>5 upper limit of normal (ULN)).
Data sourced from ClinicalTrials.gov (NCT00725452). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.